Pre-conditioning with LIFUS-driven GVs improves CD8<sup>+</sup> T cell cytotoxicity, strengthens tumor cell adhesion, reduces exhaustion signatures, and achieves durable tumor control and extended survival in orthotopic and metastatic models. This evidence concerns the gene CD8A and neoplasm.